Literature DB >> 1316028

Are oral contraceptive-associated liver cell adenomas premalignant?

L C Tao1.   

Abstract

From January 1977 to June 1990, 1,670 patients with a liver mass or masses underwent transabdominal fine needle aspiration biopsy of the liver. Of those cases, 99 were diagnosed cytologically as "hepatocellular carcinoma" and 9 as "consistent with liver cell adenoma." Among the 99 patients with hepatocellular carcinoma, 3 were users of oral contraceptives. The nine patients with liver cell adenoma were all users of oral contraceptives. Of them, two developed foci or areas of liver cell dysplasia within the adenomas. The mean periods of oral contraceptive use among these three groups of patients were different. It appeared that patients started to develop liver cell adenoma after five years of oral contraceptive use (mean, 6.3 years). Foci or areas of liver cell dysplasia began to arise within liver cell adenomas after 8 years of oral contraceptive use (mean, 9 years), and the patients started to develop hepatocellular carcinoma after 10 years of contraceptive use (mean, 11 years). The cytologic features of liver cell dysplasia strikingly mimicked those of hepatocellular carcinoma. From this study, the foci or areas of liver cell dysplasia appear to be the missing link responsible for the transformation of liver cell adenoma to carcinoma. It is believed that liver cell adenomas are not premalignant and may undergo reversible change after withdrawal of causative agents, whereas foci or areas of liver cell dysplasia within the adenomas are irreversible, premalignant changes and may transform into hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316028

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  4 in total

Review 1.  Hepatocellular carcinoma associated with anabolic steroid therapy: report of a case and review of the Japanese literature.

Authors:  A Kosaka; H Takahashi; Y Yajima; M Tanaka; K Okamura; R Mizumoto; K Katsuta
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

2.  Liver cell adenoma in a young man with elevated serum PIVKA-II level.

Authors:  H Uto; M Shigehira; T Kawano; H Nagatomo; T Kuribayashi; S Taniguchi; K Koga; N Komada; T Kitamura; T Maruyama; H Tsubouchi
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

3.  Liver cell adenoma and liver cell adenomatosis.

Authors:  Ludger Barthelmes; Iain S Tait
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 4.  Molecular pathogenesis of hepatic adenomas and its implications for surgical management.

Authors:  Siong-Seng Liau; M Saeed Qureshi; Raaj Praseedom; Emmanuel Huguet
Journal:  J Gastrointest Surg       Date:  2013-07-09       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.